Edward F. Webb

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.1kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(10), Asthma and respiratory diseases(9), Neuropeptides and Animal Physiology(9), Inflammatory mediators and NSAID effects(7), Cytokine Signaling Pathways and Interactions(5)

Publications42 total

The impact of maternal infection with latent Mycobacterium tuberculosis on infant immune sensitisation and evolution of immune responses following immunisation with BCG at birth.
Faculty of 1000 Research Ltd·2019Open Access
3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent
ACS Medicinal Chemistry Letters·2018· 9 citedOpen Access
Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases
Journal of Pharmacology and Experimental Therapeutics·2013· 76 cited
Tyrosine urea muscarinic acetylcholine receptor antagonists: Achiral quaternary ammonium groups
Bioorganic & Medicinal Chemistry Letters·2012· 3 citedOpen Access
Design, synthesis and structure–activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2012· 5 citedOpen Access
Design, Synthesis, and Structure−Activity Relationship of Tropane Muscarinic Acetylcholine Receptor Antagonists
Journal of Medicinal Chemistry·2009· 14 citedOpen Access
Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD
Bioorganic & Medicinal Chemistry Letters·2009· 7 citedOpen Access
Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists
Journal of Medicinal Chemistry·2009· 25 citedOpen Access
Discovery of Biphenyl Piperazines as Novel and Long Acting Muscarinic Acetylcholine Receptor Antagonists
Journal of Medicinal Chemistry·2008· 19 citedOpen Access
Discovery of Novel and Long Acting Muscarinic Acetylcholine Receptor Antagonists
Journal of Medicinal Chemistry·2008· 17 citedOpen Access
Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2007· 8 citedOpen Access
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
Bioorganic & Medicinal Chemistry Letters·2001· 105 citedOpen Access
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
American Journal of Physiology-Lung Cellular and Molecular Physiology·2000· 297 cited
Nonpeptide Tachykinin Receptor Antagonists. II. Pharmacological and Pharmacokinetic Profile of SB-222200, a Central Nervous System Penetrant, Potent and Selective NK-3 Receptor Antagonist
Journal of Pharmacology and Experimental Therapeutics·2000· 71 cited
SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence
Journal of Pharmacology and Experimental Therapeutics·2000· 244 cited
Renal effects of cyclooxygenase inhibitors in volume-depleted dogs
Inflammopharmacology·2000· 1 cited
Inhibition of contact sensitivity in human CD4<sup>+</sup> transgenic mice by human CD4‐specific monoclonal antibodies: CD4<sup>+</sup> T‐cell depletion is not required
Immunology·2000· 21 citedOpen Access
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
Arthritis & Rheumatism·2000· 219 cited
In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4receptor antagonist with anti-inflammatory activity
Prostaglandins Leukotrienes and Essential Fatty Acids·1999· 9 cited
SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo
Journal of Pharmacology and Experimental Therapeutics·1998· 41 cited
page 1 of 3Next →

Frequent Co-authors

Don E. Griswold(27), Henry M. Sarau(12), James J. Foley(12), Michael R. Palovich(9), Jerry L. Adams(8), Dulcie B. Schmidt(7), M Salmon(7), Miriam Burman(7), Dramane I. Lainé(7), Kristen E. Belmonte(7), John C. Lee(6), Douglas W.P. Hay(6), Paul Marshall(6), Katherine L. Widdowson(6), John Breton(5), John F. Newton(5), Nabil Hanna(5), Mark A. Luttmann(5), Leonard M. Hillegass(5), Jakob Busch‐Petersen(5)